---
title: "Novo Nordisk: \"Weight-loss miracle drug\" Semaglutide can alleviate heart failure symptoms in diabetic patients"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/201397369.md"
description: "Further supported the potential of Wegovy in treating obesity-related diseases"
datetime: "2024-04-07T08:15:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/201397369.md)
  - [en](https://longbridge.com/en/news/201397369.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/201397369.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/201397369.md) | [繁體中文](https://longbridge.com/zh-HK/news/201397369.md)


# Novo Nordisk: "Weight-loss miracle drug" Semaglutide can alleviate heart failure symptoms in diabetic patients

Novo Nordisk's popular weight-loss drug Wegovy (semaglutide) has shown in the latest large-scale clinical trials to effectively alleviate symptoms in heart failure patients with diabetes, further supporting the potential of Wegovy in treating obesity-related diseases.

A study published in the New England Journal of Medicine last Saturday reported that patients using Wegovy experienced significantly reduced fatigue, decreased leg swelling, improved breathing, and walked a longer distance in the 6-minute walk test compared to the placebo group. Additionally, these patients reported fewer severe health issues.

This study is one of the latest outcomes in a series of large trials conducted by Novo Nordisk, aiming to validate Wegovy's effectiveness in treating various obesity-related health issues including osteoarthritis and cardiovascular diseases. Novo Nordisk hopes to leverage these research findings to persuade cost-conscious insurance companies to cover the monthly cost of around $1350 for the drug.

The heart failure study published this week focused on "heart failure with preserved ejection fraction" - a condition where the heart's lower chambers fail to pump enough blood to the body. In the United States, approximately 3 million people are affected by this condition, with a global estimate of up to 32 million patients. According to a review in JAMA last year, the annual mortality rate of this disease is around 15%.

Novo Nordisk first disclosed preliminary results of the heart failure study when releasing its fourth-quarter financial report in January this year. The trial targeted obese but non-diabetic heart failure patients. The results of the two trials have been submitted for review to regulatory authorities in the United States and Europe in January

### 相关股票

- [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-CN/quote/NVO.US.md)

## 相关资讯与研究

- [British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks](https://longbridge.com/zh-CN/news/281263193.md)
- [As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?](https://longbridge.com/zh-CN/news/270794581.md)
- [Gold Hunter shifts from quiet buildup to fully funded drilling push at Newfoundland gold district](https://longbridge.com/zh-CN/news/281261616.md)
- [Warren Buffett Admits He Sold Apple Too Early, Eyes Future Buying But Not Yet](https://longbridge.com/zh-CN/news/281336451.md)
- [BUZZ-Street View: Nike's turnaround remains work in progress](https://longbridge.com/zh-CN/news/281331333.md)